Biotech · Private company · Boston, MA, US
Syntis Bio Inc
Track this companyFree. Adds Syntis Bio Inc to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards9
- Polymer Epithelial Lining for the Oral Delivery of MacromoleculesFiscal year 2026 · $1.2MNIH RePORTER 5R44DK138869-03 · fetched Nov 12, 2026
- Development of an Oral Pill to Mimic the Effects of Gastric Bypass SurgeryFiscal year 2026 · $916.7KNIH RePORTER 5R44DK141341-03 · fetched Nov 12, 2026
- Oral Therapeutics Platform for Treating Inborn Errors of Amino Acid MetabolismFiscal year 2025 · $325KNIH RePORTER 1R44DK142244-01 · fetched Nov 12, 2026
- Development of Once-daily Oral Treatment for Maple Syrup Urine DiseaseFiscal year 2025 · $343.6KNIH RePORTER 1R44DK143766-01 · fetched Nov 12, 2026
- Development of an Oral Methionine-Gamma-Lyase Enzyme for the Treatment of HomocystinuriaFiscal year 2025 · $347KNIH RePORTER 1R44HD118842-01A1 · fetched Nov 12, 2026
- Polymer Epithelial Lining for the Oral Delivery of MacromoleculesFiscal year 2025 · $1.2MNIH RePORTER 4R44DK138869-02 · fetched Nov 12, 2026
- Development of an Oral Pill to Mimic the Effects of Gastric Bypass SurgeryFiscal year 2025 · $916.4KNIH RePORTER 4R44DK141341-02 · fetched Nov 12, 2026
- Polymer Epithelial Lining for the Oral Delivery of MacromoleculesFiscal year 2024 · $349.2KNIH RePORTER 1R44DK138869-01A1 · fetched Nov 12, 2026
- Development of an Oral Pill to Mimic the Effects of Gastric Bypass SurgeryFiscal year 2024 · $322.8KNIH RePORTER 1R44DK141341-01 · fetched Nov 12, 2026